$6.21
8.07% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

uniQure N.V. Stock price

$6.21
+0.57 10.02% 1M
+1.15 22.63% 6M
-0.57 8.35% YTD
-0.45 6.76% 1Y
-24.88 80.04% 3Y
-46.67 88.26% 5Y
-5.53 47.10% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.55 8.07%
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

Key metrics

Market capitalization $302.45m
Enterprise Value $361.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.64
P/S ratio (TTM) P/S ratio 10.58
P/B ratio (TTM) P/B ratio 5.42
Revenue growth (TTM) Revenue growth -74.45%
Revenue (TTM) Revenue $28.59m
EBIT (operating result TTM) EBIT $-203.11m
Free Cash Flow (TTM) Free Cash Flow $-184.69m
Cash position $435.24m
EPS (TTM) EPS $-4.96
P/E forward negative
P/S forward 8.12
EV/Sales forward 9.58
Short interest 6.94%
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a uniQure N.V. forecast:

9x Buy
69%
4x Hold
31%

Analyst Opinions

13 Analysts have issued a uniQure N.V. forecast:

Buy
69%
Hold
31%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
29 29
74% 74%
100%
- Direct Costs 39 39
137% 137%
136%
-10 -10
111% 111%
-36%
- Selling and Administrative Expenses 34 34
36% 36%
120%
- Research and Development Expense 146 146
11% 11%
510%
-191 -191
55% 55%
-667%
- Depreciation and Amortization 12 12
24% 24%
44%
EBIT (Operating Income) EBIT -203 -203
53% 53%
-710%
Net Profit -240 -240
5% 5%
-838%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Neutral
GlobeNewsWire
11 days ago
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~
Neutral
GlobeNewsWire
about one month ago
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismuta...
Neutral
GlobeNewsWire
about 2 months ago
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure's investigational gene therapy for the treatment of Fabry disease, a rare,...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 480
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today